ACXP•benzinga•
Acurx Pharma Says Lead Antibiotic Candidate, Ibezapolstat, Is Ready To Advance To International Pivotal Phase 3 Clinical Trials For Treatment Of Patients With C. Difficile Infection
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 9, 2025 by benzinga